TDP-43 is an RNA/DNA-binding protein of versatile physiological functions and it is also implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) disease in addition to several other implicated proteins such as mutant SOD1 and FUS etc.
Introduction
Aggregation of misfolded proteins into amyloid-like aggregates is a prominent feature of several neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and Parkinson's disease etc. [1] [2] [3] [4] [5] . Amyloids can be formed by several proteins and peptides and they are ordered aggregates formed by conformational changes in the normally soluble proteins which thereafter assemble into insoluble aggregates that are partially resistant to protease degradation [1, [5] [6] [7] [8] [9] . The structure of amyloid aggregates consists predominantly of β-sheets arranged in a cross-β conformation where the β-strands are arranged perpendicular to the fiber axis [10] . Amyloid aggregates can bind to flat dyes such as thioflavin-T and Congo red and their binding characteristically alters the spectroscopic properties of these dyes [10] [11] [12] [13] . Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurodegenerative disease associated with motor neuron degeneration [14] [15] [16] .
Although most of the ALS cases (~90%) are sporadic, about 5-10% of ALS cases are familial and follow Mendelian inheritance of mutations in several genes of which SOD1, TARDBP, C9ORF72 and FUS are prominent [5, [17] [18] [19] [20] . About 97% of the ALS patients harbor deposition of aggregated TAR-DNA binding protein (TDP)-43 in the disease affected tissues [5, 21] . In addition to ALS and a subset of frontotemporal lobar degeneration (FTLD-TDP-43), TDP-43 aggregates have also been found to be present in many other neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [5, 22, 23] .TDP-43 is a ubiquitously expressed versatile RNA/DNA-binding protein and its N-terminal domain contains dominant inheritance [18, [37] [38] [39] . In fact, overexpression of the mutant human TDP-43-A315T leads to alteration in the TDP-43 expression levels, function, increased phosphorylation, fragmentation, aggregation, mitochondrial aggregation and dysfunction, ER stress, autophagy and neurodegeneration in different models [33, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . Furthermore, in vitro studies have revealed that a peptide fragment (aa: 286-331) having A315T familial mutation is also amyloidogenic and neurotoxic [33] .
Also, in an in vitro study, a mutant TDP-43 A315T peptide (307-319) was found to form an anti-parallel β-sheet structure bearing thick, long and straight fibrils and was also found to be neurotoxic [52] . Recently, membrane-less liquid droplet-like organelles formed by the proteins containing prion-like low complexity domains (LCD) are being implicated in several neurodegenerative diseases including ALS [5, [53] [54] [55] [56] . The process of formation of these membrane-less liquid droplet-like organelles is termed as liquid-liquid phase separation (LLPS) [55, 57] . Proteins containing prion-like LCDs can undergo phase-separation upon addition of salt, or alteration in pH or temperature, through transient intermolecular interactions such as the hydrophobic, cation- and - interactions [58] . TDP-43 contains an LCD and can undergo LLPS in the presence of salt or due to post-translational modifications like poly ADP-ribosylation (PARylation) [59] . Strikingly, depletion of RNA concentration was found to enhance the LLPS of TDP-43 and in contrast increase in the RNA to protein stoichiometry was found to prevent and also reverse the LLPS of TDP-43 [60] . It has been proposed that LLPS is a precursor process for the formation of terminally irreversible pathogenic aggregates of TDP-43, thus, finding any molecules inhibitory to LLPS will be of high significance [61] . The aggregation of TDP-43 has been proposed to cause cytotoxicity via several mechanisms such as oxidative stress induction, mitotoxicity, vacuolar fragmentation and RNA metabolism dyshomeostasis etc. therefore, TDP-43 is considered as an important protein target for screening of drugs against ALS and other TDP-43 proteinopathies [5, 28, [62] [63] [64] . Thus far, no effective cure or treatment exists for ALS. A small molecule, riluzole, which is an inhibitor of glutamate mediated-excitotoxicity and another molecule edaravone (also called radicava), a potent pyrazolone free radical scavenger and an antioxidant, are the two FDA-approved drugs available thus far for ALS for selected patients and these may increase survival by approximately two to three months only [65, 66] . Current research on ALS therapeutics focuses on strategies including pro-survival signaling of motor neurons, improving mitochondrial function and anti-oxidant response and anti-aggregation approaches such as using small interfering RNA and antisense oligonucleotides [5, 67, 68] . In a recent study, towards therapeutic approach, over-expressions of the yeast cochaperone Sis1 (Hsp40) as well as its human homolog DNAJB1 could reduce the TDP-43 toxicities respectively in the yeast cells and primary cortical neurons thereby asserting that the modulation of chaperone activity may be a potentially fruitful strategy to pursue towards ALS therapeutics [69] . In another approach, small molecules like methylene blue and dimebon were found to inhibit the TDP-43 aggregation in cell lines but these unfortunately failed further in the clinical trials [70] . In our recent study, where several imidazolium derivatives of acridine were screened, AIM4 was found to have high anti-TDP-43 aggregation effects in the yeast model expressing TDP-43-YFP and also in vitro as tested against a recombinantly purified C-terminal aa: 193-414 fragment (TDP-43 2C ) [30, 71, 72] . However, the mechanism by which AIM4 inhibits TDP-43 aggregation remains to be elucidated thus whether it has any binding affinity to TDP-43 needs to be determined. Also, as TDP-43 is highly aggregation-prone and needs to be maintained in presence of denaturants, it thwarts the usage of traditional tools such as isothermal titration calorimetry (ITC) to determine the AIM4's binding affinity.
Therefore, in this study computational tools like molecular docking and molecular dynamic simulations, were used to get insights into the binding mechanism of AIM4 to TDP-43. For comparison, we examined several other acridine imidazolium derivatives [71, 72] and a previously reported anti-TDP-43 aggregation molecule dimebon. Dimebon has been previously shown to exhibit anti-aggregation effects on TDP-43 in SH-SY5Y cells [70] . Another small anti-amyloidogenic molecule, DPH, that is thus far not known to influence the TDP-43's aggregation has also been examined here for comparison [70] . As LLPS has been suggested to be a precursor process for the aggregation and deposition of TDP-43 as well as many other RNA binding proteins, therefore, we also examined whether AIM4 can inhibit the in vitro LLPS of the TDP-43 2C bearing an A315T familial ALS mutation. Together, we attempted here to investigate the potential binding site(s) of AIM4 on TDP-43 and its potential application towards inhibiting the liquid-liquid phase separation behavior of TDP-43 which is proposedly pathogenic for ALS.
Materials and methods

Materials
Ni-NTA agarose was purchased from Qiagen (USA). Alexa Fluor, Thioflavin-T (ThT), Tris-base, ampicillin, chloramphenicol, sodium dodecyl sulfate (SDS), sarkosyl, dithiothreitol (DTT), phenylmethanesulfonyl fluoride (PMSF), isopropyl β-D-1-thiogalactopyranoside (IPTG), and imidazole were procured from Sigma (USA). Guanidine hydrochloride (GdnHCl), TCEP ammonium persulphate (APS) were purchased from SRL (India). Bradford's protein concentration estimation reagent was from Bio-Rad (USA). EDTA-free protease inhibitor cocktail was purchased from Roche Diagnostics (Switzerland). Agarose, Coomassie brilliant blue R-250, tetramethylethylenediamine (TEMED), sodium phosphate dibasic and sodium phosphate monobasic were purchased from HiMedia Lab (India). Urea was purchased from Affymetrix (USA). Restriction enzymes were procured from NEB BioLabs (USA). Dimebon was purchased from Sigma (USA). Diphenhydramine hydrochloride (DPH) was procured from TCI chemicals (Canada). Alexafluor 488 C5 malemide (catalogue number: A10254) was purchased from Thermofischer scientific, USA.
Receptor and ligand preparation
Protein structure
In previous studies, several available structures of small segments of amyloid forming proteins have been capitalized for the design of inhibitors of fibril formation [73, 74] . In this study, we used a Cryo-EM determined structure of a small fragment of ALS familial mutant A315E TDP-43 encompassing amino acids from aa: 288-319 (PDB ID: 6N3C, originally termed as SegB) [75] . This is a fibrillar structure of a speculated pathogenic core involved in human TDP-43 aggregation which proposedly participates in the formation of both reversible and irreversible aggregates [75] . The different chains in the 6N3C fibril structure have been labeled from A to T. We introduced another familial point mutation, A315T, in the 6N3C structure, by using the Swiss PDB viewer [76] and this structure, represented hereby as 6N3C-A315T, has been used along with the structures 6N3C for docking and MDS studies. All the ligand structures were docked sequentially to the two fibrillar structures. We also used crystal structures of the potential amyloidogenic C-terminal fragments whose PDB IDs and the amino acid numbers are: 5WIA (aa: 370-375), 5WIQ (aa: 396-402), 5WKD (aa: 300-306), 6CB9 (aa: 328-333), 6CEW (aa: 321-326), 6CFH (aa: 333-343), 5WHN (aa: 312-317), 5WHP
(aa: 312-317 having a point mutation A315T), 6CF4 (aa: 312-317 having A315T mutation and phosphorylated Thr-315) and 5WKB (aa: 312-317 having point mutation A315E) [25] . In addition to the C-terminal region of TDP-43, the available structures of the tandem RRM domains (PDB ID: 4BS2, aa: 96-269) [77] and Nterminal domain (NTD) (PDB ID: 2N4P, aa: 1-89) [78] were also used for the docking studies. The overall domain architecture of TDP-43, also highlighting the amyloidogenic C-terminal region peptides, has been schematically depicted in Ligand structure AIM4 and other acridine-imidazolium derivatives previously examined in vitro for its propensity of anti-aggregation effects on wild-type TDP-43 2C , were used as test compounds for docking studies [71, 72] . For comparison, certain other ligands such as dimebon and diphenhydramine hydrochloride (DPH) which have already been tested in cellular models for their inhibitory activity on TDP-43 aggregation were also used [70] . Structures of the available compounds available were retrieved in sdf format from PubChem and then converted to PDB format using Open Babel [79] .
For the test ligands and other ligands whose structures were not available, the structures were first drawn using Marvin Sketch (ChemAxon), and then hydrogen atoms were added and finally the structures were 3D-cleaned and saved in '.pdb'
format. Furthermore, all the ligand structures were geometrically optimized by using Avogadro software before docking [80] . The structures of all the ligands used for docking to TDP-43 are depicted in Figure 1 .
Molecular docking
The docking studies were performed using open source software, AutoDock 4.2.
ADT (AutoDock Tool), which is a graphic user interface, was used for preparing the protein and ligand structures for docking. ADT was also used to make the grid and the docking parameter files [81] . The protein and ligand structures were prepared for docking by adding gasteiger charges. Blind docking was carried out for the 6N3C, 6N3C-A315T and TDP-43 (aa: 288-319) with all the ligands. The docking space was defined by constructing a grid box. The dimensions of the grid box were set such that the entire protein structure could fit inside the grid box. Grid maps were calculated for each atom type present in the ligand. The spacing between the grid points was set to 0.669 Å. The docking parameters were set to 100 GA runs and 2,500,000 energy evaluations for each cycle. Lamarckian genetic algorithm was used for the docking [82] . For a particular conformation of the protein, the grid and docking parameters were maintained the same for all ligands. After analysis of the docking results, the protein ligand complexes were generated using ADT. Docking parameters were kept the same for the RRMs (4BS2), NTD (2N4P) and the CTD peptide structures, as described above.
Molecular dynamics simulation
MD simulations were performed by using Desmond package of Schrodinger (D. E. Shaw Research, New York, NY, USA) [83] . The protein-ligand complexes having the best binding energies were used for the simulations in order to check the stability and flexibility of the complexes. Before the simulation, each complex was optimized with protein preparation wizard in the Maestro 11.0 (Maestro, Schrödinger, LLC, New York, NY, 2017) by assigning proper bond orders and optimizing the hydrogen bonds. Further, the complex structures were minimized using OPLS3 force field [84] . PROPKA was used to determine the protonation status at pH 5.0 [85] . The complex structures were solvated with pre-defined single point charge (SPC) water model orthorhombic box shape (a=b=c=10Å, α=β=ϒ=90°). The entire system was neutralized by adding proper counter ions (Na + or Cl -). The placement of ions in the solvated system was random. The salt, NaCl, was also added to the solvated system at 0.30M concentration. After building the solvated system, the system was energy minimized and relaxed using the default relaxation protocol of Desmond. This default relaxation protocol includes two rounds of energy minimization steps and four short MD simulation steps. The energy minimization was done by steepest descent method with a maximum of 2000 steps with and without restraints (force constant of 50 kcal/mol/Å on all solute atoms). The energy minimization steps followed by four short MD simulations are: 1) 12 picoseconds MD simulation at 10 K temperature in the Berendsen NVT ensemble (constant number of particles, volume, and temperature) with solute heavy atoms restrained (force constant of 50 kcal/mol/Å); 2) 12 picoseconds simulation at 10 K in the Berendsen NPT ensemble (constant number of particles, pressure, and temperature) with the same restraints on solute heavy atoms; 3) 12 picoseconds simulation in Berendsen NPT ensemble using the same restraints on solute heavy atoms in which the temperature was raised to 300 K; and 4) a final 24 picoseconds simulation in the Berendsen NPT ensemble at 300 K without restraints [86, 87] . After relaxation of the system, production MD simulation was performed using OPLS3 force field [84] . The temperature was kept at 300K using Nose-Hoover chain method [88] and pressure was kept at 1 bar using Martyna-Tobias-Klein method [89] . RESPA integrator was used for all simulations with default values : 2.0 femtoseconds time step for bonded interaction and short range non-bonded interactions whereas 6.0 femtoseconds time step for the longrange non-bonded interactions [90] . The production simulation was run in NPT ensemble for either 100 or 300 ns.
MD simulation analysis
The MD simulation results were analyzed using Maestro software of Schrodinger [91] . Simulation interactions diagram (SID) program available with the Desmond module was used to analyze protein-ligand RMSD, protein RMSF, ligand RMSF and protein-ligand interactions [83] . All the atoms were selected for RMSD and RMSF calculations. All the analyses were done for the entire range of the simulation time. At the end of the simulation, ligand binding energy (in kcal/mol) to its receptor was calculated using MM-GBSA tool of the Prime suite of Schrodinger (Prime, Schrödinger, LLC, New York, NY, 2017). For the energy calculation, the input partial charge of the ligand was used instead of assigning partial charges by using default force field. Protein residues within 5 Å distance of the ligand were allowed to be flexible for the energy calculation [92] . These primers were designed to incorporate a KpnI restriction enzyme recognition site (GGTACC). After DpnI digestion of the template DNA, the PCR product was transformed into competent DH5α E. coli cells (Invitrogen, USA). Then, plasmids were isolated from the obtained transformants and analyzed for positive KpnI digestion to ascertain for the successful mutagenesis.
Plasmids and site-directed mutagenesis
Recombinant protein expression and affinity purification
For recombinant protein expression, the pET15b-His-TDP-43 2C (A315T) plasmid constructed here as described above, was first transformed into the expression competent Rosetta 2 (DE3) E. coli cells (Novagen, USA). Expressions of the mutant TDP-43 2C -A315T protein and its affinity purification was carried out following prior published methods with minor modifications [30, 71] . Briefly, the Figure S3 ).
Amyloid-like aggregation kinetics of TDP-43 2C -A315T and inhibition by AIM4 and AIM1
Before using for the aggregation, the 6M GuHCl in the protein sample was first replaced with 4M urea. For this, the TDP-43 2C -A315T purified in 6M GuHCl was first diluted 10-fold in PBS pH 7.5 which causes the precipitation of TDP-43 2C -A315T [71] . The precipitate was then pelleted by centrifugation at 14000 x g for 10 min at 4 °C and the supernatant was discarded to remove GuHCl. The pellet was then re-suspended and dissolved in 4M urea in PBS pH 7.5 and used for the aggregation following the method as described previously [71] . nm upon excitation at 442 nm [11, 71] . For examining their inhibitory potential towards the aggregation of mutant TDP-43 2C -A315T, first 50 mM stock solutions of the acridine imidazolium derivative compounds AIM4 and AIM1 were prepared in 25% DMSO [71, 72] . Then the compounds were added to the aggregation solution containing 400 µM of mutant TDP-43 2C -A315T, at a protein: AIM4/AIM1 ratio of 1:10, 1:15 or 1:20. Any inhibition of the aggregation was examined by recording the ThT emission fluorescence as described above. A315T. The precipitate was then pelleted by centrifugation at 14000 x g for 10 min at 4 °C and the supernatant was discarded to remove GuHCl. The pellet was then re-suspended and dissolved in 8M urea in PBS pH 7.5. 
Phase separation analysis by fluorescence microscopy
Results and discussion
Docking of AIM4 and other compounds with different known structures of
TDP-43 (PDB IDs: 6N3C, 4BS2 and 2N4P)
In our previous study, we tested several acridine imidazolium derivatives and found that AIM4 was the most effective ligand to inhibit the in vitro aggregation of the TDP-43 2C [71] . AIM4 also effectively inhibited full-length TDP-43 aggregation in the yeast model. So far, the mechanism of AIM4 mediated anti-aggregation of TDP-43 is not deciphered. Thus, in an attempt to decipher the mechanism of AIM4 mediated anti-aggregation of TDP-43, we first examined the binding of AIM4 to several pre-determined structured of TDP-43, using molecular docking tool, AutoDock. Recently, the structure of a C-terminal fragment of TDP-43, which has been speculated to be a pathogenic core segment (residues 286-331 with A315E mutation) was solved using cryo-electron microscopy (PDB ID: 6N3C). To this fibrillar 6N3C structure we also performed another mutation to replace E by T to generate A315T familial ALS mutation. The two structures, 6N3C and 6N3C-A315T (288-319) were used for docking studies. In addition to the fibrillar structure 6N3C, we also used structures of TDP-43 tandem RRMs (PDB: 4BS2) and Nterminal region (PDB: 2N4P) for docking experiments.
We used the most effective anti-aggregation acridine derivative, AIM4, along with two other acridine derivatives which exhibited partial inhibitory potential towards TDP-43 aggregation, namely, AIM1 and AIM3, to carry out the docking studies with the known structures of TDP-43. As a control, we used dimebon which has been previously shown to inhibit the TDP-43's aggregation in the cellular models and also an anti-histaminergic compound diphenhydramine hydrochloride (DPH) which did not affect the TDP-43 aggregation.
Initially, we allowed all the five ligands to bind to various TDP-43 structures by blind docking and calculated the binding energy by AutoDock. For 6N3C and 6N3C-A315T, AIM4 exhibited better binding energy over the other four ligands (Figure 2a and Table 1 ). This finding that AIM4 binds better than the other ligands in the C-terminal region of TDP-43 correlates with the data obtained earlier on the in vitro TDP-43 2C structure, which also encompasses the amino acids from 288-319 of 6N3C [71] .
Next, to examine if AIM4 has any other binding sites in the TDP-43 structure, we further performed a blind docking of all the five ligands to the structures of the TDP-43's tandem RRMs (aa: 96-269; PDB ID: 4BS2) [77] . The tandem RRM region has high significance as TDP-43 interacts with the RNA molecules via the RRMs and the RNA interaction has been reported to inhibit TDP-43 from condensing into phase-separated liquid droplets, which are speculated to be precursor of its terminal irreversible amyloid-like aggregation [60] . As with the Cterminal region of TDP-43, AIM4 also exhibited better binding energy in comparison with all other ligands when docked to the tandem RRM structure (Figure 2a and Table 1 ).
Additionally, the N-terminal region of TDP-43 has also been proposed to play a role in the aggregation of TDP-43 [93] . Therefore, blind docking of the ligands were also carried out against the available solution NMR structure of an N-terminal region (aa: 1-89; PDB ID: 2N4P) of TDP-43 (Figure 2a) . We chose the best representative conformer of 2N4P and docked it with all the ligands. In this N-terminal TDP-43 structure, dimebon yielded better docking energy than AIM4 thereby suggesting of its better binding affinity than AIM4 to the N-terminal region (Figure 2a and Table   1 ). Taken together, the docking results predict that AIM4 may prefer to bind to the aggregation prone C-terminal region of TDP-43 and the tandem RRMs over the Nterminal region. 2b and Table 2 ). Similarly, for the four peptides which form labile aggregates (5WHN, 5WHP, 5WKB and 6CF4), the AIM4 molecule had better affinity than all the other tested ligands (Figure 2b and Table 2 ). Among the four structures, the docking energy of AIM4 with 5WHN was predicted to be significantly better than that of the other ligands (-13.43 kcal/mol) with a predicted inhibition constant (Ki) of 0.14 nM (Figure 2b and Table 2 ). 
MD simulation suggests that AIM4 forms stable complex with 6N3C and 6N3C-A315T TDP-43 (aa: 288-319)
Next, we analyzed the conformational changes of the AIM4 bound TDP-43 structure complexes through molecular dynamic (MD) simulations. First, we subjected the complex of AIM4 with 6N3C (TDP-43 aa: 288-319 A315E mutant) to molecular dynamics simulation for a period of 300 nanoseconds (Figure 3) . The MD simulation revealed that the trend of the mutant 6N3C-AIM4 (protein-ligand) RMSD against the simulation time was found to plateau and the average proteinligand RMSD (2.8±0.8 Å) was nearly same as that of protein alone RMSD (2.6±0.2 Å), thereby suggesting that the complex is stable (Figure 3a) . Along with RMSD, protein-RMSF (root mean square fluctuation) and ligand-RMSF were also monitored to assess the local residue flexibility of the protein and the atom-wise fluctuations in the ligand (Figure 3b ). Total number of contacts that were made between the mutant A315E TDP-43 peptide and AIM4 and maintained throughout the course of simulation time are depicted (Figure 3c) . Gly-288 and Asn-291 were found to be the key residues interacting with AIM4 throughout the simulation period and these interactions were mediated majorly through H-bond (Figure 3d ). Over the time course of MD simulation, the protein-ligand contacts retained throughout the simulation period, have been shown as a timeline representation of number of contacts made by each residue with the ligand in each trajectory frame (Figure 3e ). showing the residues of mutant A315E TDP-43 interacting with the ligand (AIM4) in each trajectory frame. Some residues make more than one specific contact with the ligand, which is represented by a darker shade of orange, according to the scale to the right of the plot. Fibrillar structure of 6N3C contains several chains from A to T which are appropriately labeled for its AIM4 interaction.
Next, we analyzed the MD simulation of the complex of mutant 6N3C-A315T with AIM4 to assess the stability of the complex. The RMSD of the complex was found to be stabilized after around 80 th nanosecond (Figure 4a) . The trend of the 6N3C-A315T-AIM4 (protein-ligand) RMSD against simulation time showed that the complex is stable (Figure 4a) . The average protein-ligand RMSD (2.9±0.8 Å) was nearly same as that of protein alone RMSD (2.6±0.2 Å). Protein-RMSF (root mean square fluctuation) and ligand-RMSF were also monitored to assess the local residue flexibility of the protein and the atom-wise fluctuations in the ligand (Figure 4b) .
Total contacts which were maintained throughout the simulation time have also been depicted (Figure 4c ). Gly-288 and Phe-289 were found to be the key residues interacting with AIM4 throughout the simulation period (Figure 4d) . These interactions were mediated majorly through hydrogen and hydrophobic bonds. Over the time course of MD simulation, the protein-ligand contact was retained throughout the simulation period as shown by timeline representation of number of contacts made by each residue with the ligand in each trajectory frame (Figure 4e) .
Notably, key residues for LLPS contain a GFG motif and from the results of the simulation it is seen that glycine-288 and phenylalanine-289 are the key residues through which AIM4 interacts. . it shows the residues of mutant A315T TDP-43 interacting with the ligand (AIM4) in each trajectory frame. Some residues make more than one specific contact with the ligand, which is represented by a darker shade of orange, according to the scale to the right of the plot. Fibrillar structure of 6N3C contains several chains from A to T which are appropriately labeled for its AIM4 interaction.
Next, to assess the stability of the AIM4 binding to the RRMs of TDP-43 (aa: 96-269; PDB ID: 4BS2) complex, MD simulation of 4BS2-AIM4 complex was carried out for 100 nanoseconds. The RMSD plot of the protein-ligand complex did not plateau and displayed increasing trend towards the end of simulation indicating that the complex was not stable. Over the 100 ns of simulation period, the average RMSD values for protein alone (6.7±2.5 Å) was observed to be very high indicating that the protein is undergoing a large conformational change during the simulation.
Also, the high average value of protein-ligand (8.2±2.9 Å) RMSD suggested that the 4BS2-AIM4 complex is unstable ( Supplementary Figure S1 ). 
Next
Binding free-energy calculations of 6N3C-AIM4 and 6N3C-A315T-AIM4 complexes from MD simulations
The binding free-energies of the complexes of the ligands with 6N3C or 6N3C-A315T mutant TDP-43 (288-319) were averaged at the end of the simulations over the last 25 ns using MMGBSA approach (Prime package of Schrodinger) [94] . The average binding free energy for the AIM4 with 6N3C was found to be -52.38
kcal/mol and in case of AIM4 with 6N3C-A315T was -52.78 kcal/mol. 
AIM4 also inhibits amyloid-like aggregation of TDP-43 2C -A315T
Since, AIM4 binding was stable with the familial mutant A315T and exhibited better docking energy, we decided to investigate the effects of AIM4 on an ALS-related familial mutant of TDP-43, A315T mutant of TDP-43 2C was generated and examined for its in vitro aggregation kinetics. As a control, we also tested the second best acridine TDP-43 2C inhibitor AIM1 for comparison. Similar to as reported for the wild-type protein [71] , TDP-43 2C -A315T also showed ThT fluorescence kinetics akin to that of an amyloid-like aggregation (Figure 6) . Furthermore, alike the wildtype TDP-43 2C protein [71] , concentration-dependent inhibition of the aggregation of TDP-43 2C -A315T was also observed in the presence of AIM4 and AIM1 ( Figure   6 ). like TDP-43 [5, 95] . From our in silico studies, in the 6N3C-A315T mutant TDP-43 structure (aa: 288-319), AIM4 was predicted to interact with the major amino acids, glycine and phenylalanine, which are proposedly involved in its pathogenic LLPS [95] . Therefore, the effect of AIM4 on the in vitro LLPS of mutant TDP-43 2C -A315T, that also encompasses the aa: 288-319, was checked. Several reports have previously shown that TDP-43 and its prion-like C-terminal domain can undergo LLPS which can be modulated by the presence of salt, RNA or post-translational modifications like the addition of poly(ADP-ribose) [59, 60, 95, 96] . Recently, alexafluor labelled TDP-43 has been shown to form phase separated droplets [97] .
In agreement, we found that after incubation under aggregation conditions, alexafluor labelled mutant TDP-43 2C -A315T underwent transition from a soluble state to form liquid-droplets, when observed under fluorescence microscopy ( Figure   7 ). To investigate if the acridine compounds AIM4, AIM1 or AIM3 could also modulate the liquid-liquid phase separation behavior of TDP-43 2C , in vitro phase separation assay was performed in the presence of these acridine compounds (protein: compound molar ratio-1:15). We observed that indeed the presence of AIM4 inhibited the formation of liquid droplet assemblies (i.e LLPS) in the mutant TDP-43 2C -A315T whereas, the samples lacking AIM4 manifested numerous liquid droplets as previously reported by other groups (Figure 7a) . When the presence of liquid phase-separated droplets was examined, there was no visible phase separation in the TDP-43 2C -A315T sample incubated along with AIM4 at 1:15 ratio of the protein to AIM4. In comparison AIM1 could greatly reduce the number of phase separated liquid droplets but unlike AIM4, AIM1 could not completely abrogate LLPS (Figure 7a and 7b) . a. Mutant A315T TDP-43 2C , labelled with Alexa Fluor™ 488 C5 maleimide undergoes transition from soluble state to liquid droplets suggesting of a process termed as liquidliquid phase separation (LLPS). Mutant TDP-43 2C -A315T (400 µM) was incubated at 37 °C in aggregation buffer (2.5M urea-PBS), either alone or with the additions of 1:15 (protein: compound molar ratio) of AIM4, AIM3, AIM1, DPH or dimebon, for a period of 5 hours. The Alexa Fluor-bound species appear as droplets as observed under fluorescence microscopy when examined using the GFP filter. With acridine compounds, AIM3 which affected TDP-43 2C aggregation to the least extent exhibited the formation of irregular solid shaped aggregates, whereas AIM1 which moderately inhibits TDP-43 2C aggregation, the formation of these liquid droplets gradually decreased and were present in far fewer numbers in comparison with the protein sample without any inhibitor and with AIM4, which exhibits maximum inhibitory potential to TDP-43 2C , the liquid droplets completely disappeared thereby indicating a complete inhibition of LLPS. All the images were taken at 10X magnification. b. The total number of liquid droplets found in each frame of the Alexa Fluor labelled protein without any inhibitor as well as with 1:15 (protein: compound molar ratio) of AIM1 and AIM4 were counted. The data represents the number of droplets found in 18 frames for each of the sample.
Conclusion
Owing to the importance of inhibition of TDP-43 aggregation and the current unavailability of effective drugs against ALS, a small molecule AIM4 had been previously demonstrated to be a candidate for the inhibition of the TDP-43
aggregation [71] . Here, mechanism of AIM4-mediated inhibition was investigated through computational tools and it was further examined if AIM4 can also inhibit the mutant TDP-43 2C -A315T's amyloid-like aggregation and liquid-liquid phase separation, the potential precursor process leading to its aggregation [99] . Recently, a cryo-EM structure was solved from the core amyloidogenic region (aa: 288-319;
PDB ID: 6N3C) of TDP-43 having A315E familial ALS mutation [75] and here another familial A315T mutation was incorporated in silico into the 6N3C structure and these two structures were used for examining AIM4's affinity. In addition, other known structures from TDP-43 sequence namely, tandem RRMs (aa: 96-269;
PDB ID: 4BS2), N-terminal domain (aa: 1-89; PDB ID: 2N4P) and ten amyloidogenic peptide fragments from the low complexity domain (LCD) of TDP-43, were also used to predict the binding site of AIM4. Computational studies predicted better binding of AIM4 than the other used ligands to the aa: 288-319 amyloidogenic core region of TDP-43 with the A315E and A315T familial mutations. Also, from the in silico studies, in the 6N3C-A315T mutant TDP-43 structure (aa: 288-319), AIM4 was predicted to interact preferentially with two amino acids, glycine and phenylalanine which are also already known to be involved in its pathogenic liquid-liquid phase separation (LLPS). Therefore, the ability of 
